LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma

References

• Frezza AM, Stacchiotti S, Gronchi A. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017;15(1):1–11. doi:10.1186/s12916-017-0872-y.
   PubMedGoogle Scholar
• Ayodele O, Abdul Razak AR. Immunotherapy in soft-tissue sarcoma. Curr Oncol. 2020;27(February):17–23. doi:10.3747/co.27.5407.
   PubMedGoogle Scholar
• Banks LB, D’Angelo SP. The role of immunotherapy in the management of soft tissue sarcomas: Current landscape and future outlook. JNCCN J Natl Compr Cancer Netw. 2022;20(7):834–844. doi:10.6004/jnccn.2022.7027.
   PubMed Web of Science ®Google Scholar
• Birdi HK, Jirovec A, Cortés-Kaplan S, Werier J, Nessim C, Diallo JS, Ardolino M. Immunotherapy for sarcomas: new frontiers and unveiled opportunities. J Immunother Cancer. 2021;9(2):1–12. doi:10.1136/jitc-2020-001580.
   Web of Science ®Google Scholar
• Granhøj JS, Witness Præst Jensen A, Presti M, Met Ö, Svane IM, Donia M. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions. Expert Opin Biol Ther. 2022;22(5):627–641. doi:10.1080/14712598.2022.2064711.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–4557. doi:10.1158/1078-0432.CCR-11-0116.
   PubMed Web of Science ®Google Scholar
• Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Hendel HW, Hölmich LR, Hendel HW, Met Ö, Andersen MH. Long-lasting complete responses in patients with metastatic melanoma after Adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res. 2016;22(15):3734–3745. doi:10.1158/1078-0432.CCR-15-1879.
   PubMed Web of Science ®Google Scholar
• Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113–2125. doi:10.1056/NEJMoa2210233.
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu Y, Dudley ME, Parkhurst MR, Yang JC, Rosenberg SA, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Sci. 2014;9(80May):641–645. doi:10.1126/science.1251102.
   Google Scholar
• Zacharakis N, Chinnasamy H, Black M, Xu H, Lu Y-C, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–730. doi:10.1038/s41591-018-0040-8.
   PubMed Web of Science ®Google Scholar
• Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543–1550. doi:10.1200/JCO.2014.58.9093.
   PubMed Web of Science ®Google Scholar
• Kverneland AH, Pedersen M, Wulff Westergaard MC, Nielsen M, Borch TH, Olsen LR, Aasbjerg G, Santegoets SJ, van der Burg SH, Milne K, et al. Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. Oncotarget. 2020;11(22):2092–2105. doi:10.18632/oncotarget.27604.
   PubMedGoogle Scholar
• Kverneland AH, Chamberlain CA, Borch TH, Nielsen M, Mørk SK, Kjeldsen JW, Lorentzen CL, Jørgensen LP, Riis LB, Yde CW, et al. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. J Immunother Cancer. 2021;9(10):1–11. doi:10.1136/jitc-2021-003499.
   Web of Science ®Google Scholar
• Haug BE, Camilio KA, Eliassen LT, Stensen W, Svendsen JS, Berg K, Mortensen B, Serin G, Mirjolet JF, Bichat F, et al. Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptide. J Med Chem. 2016;59(7):2918–2927. doi:10.1021/acs.jmedchem.5b02025.
   PubMed Web of Science ®Google Scholar
• Sveinbjørnsson B, Camilio KA, Haug BE, Rekdal Ø. LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment. Futur Med Chem. 2017;9(12):1339–1344. doi:10.4155/fmc-2017-0088.
   PubMed Web of Science ®Google Scholar
• Camilio KA, Berge G, Ravuri CS, Rekdal Ø, Sveinbjørnsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother. 2014;63(6):601–613. doi:10.1007/s00262-014-1540-0.
   PubMed Web of Science ®Google Scholar
• Nestvold J, Wang MY, Camilio KA, Zinöcker S, Tjelle TE, Lindberg A, Haug BE, Kvalheim G, Sveinbjørnsson B, Rekdal Ø. Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. Oncoimmunology. 2017;6(8):1–12. doi:10.1080/2162402X.2017.1338236.
   Web of Science ®Google Scholar
• Liao HW, Garris C, Pfirschke C, Rickelt S, Arlauckas S, Siwicki M, Kohler RH, Weissleder R, Sundvold-Gjerstad V, Sveinbjørnsson B, et al. LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects. Cell Stress. 2019;3(11):348–360. doi:10.15698/cst2019.11.204.
   PubMedGoogle Scholar
• Jebsen NL, Apelseth TO, Haugland HK, Rekdal Ø, Patel H, Gjertsen BT, Jøssang DE. Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report. J Med Case Reports. 2019;13(1):1–9. doi:10.1186/s13256-019-2088-6.
   PubMedGoogle Scholar
• Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, et al. Safety, antitumor activity, and T-cell responses in a dose-ranging phase I trial of the oncolytic peptide LTX-315 in patients with solid tumors. Clin Cancer Res. 2021;27(10):2755–2763. doi:10.1158/1078-0432.CCR-20-3435.
   PubMed Web of Science ®Google Scholar
• World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346–2357. doi:10.1200/JCO.2005.00.240.
   PubMed Web of Science ®Google Scholar
• Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met O, Hölmich LR, Andersen RS, Hadrup SR, Andersen MH, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients. J Transl Med. 2012;10(1):169. doi:10.1186/1479-5876-10-169.
   PubMed Web of Science ®Google Scholar
• Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother (1991). 2008;31(8):742–751. doi:10.1097/CJI.0b013e31818403d5.
   PubMed Web of Science ®Google Scholar
• Donia M, Junker N, Ellebaek E, Andersen MH, Straten PT, Svane IM. Characterization and comparison of ‘standard’ and ‘Young’ tumour-infiltrating lymphocytes for Adoptive cell therapy at a Danish translational research institution. Scand J Immunol. 2011;75(2):157–167. doi:10.1111/j.1365-3083.2011.02640.x.
   Web of Science ®Google Scholar
• Donia M, Larsen SM, Met O, Svane IM. Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the wave bioreactor. Cytotherapy. 2014;16(8):1117–1120. doi:10.1016/j.jcyt.2014.02.004.
   PubMed Web of Science ®Google Scholar
• DeWitt WS, Emerson RO, Lindau P, Vignali M, Snyder TM, Desmarais C, Sanders C, Utsugi H, Warren EH, McElrath J, et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. J Virol. 2015;89(8):4517–4526. doi:10.1128/jvi.03474-14.
   PubMed Web of Science ®Google Scholar
• Rytlewski J, Deng S, Xie T, Davis C, Robins H, Yusko E, Bienkowska J, Beavis PA. Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood. PLos One. 2019;14(3):1–10. doi:10.1371/journal.pone.0213684.
   Web of Science ®Google Scholar
• Nielsen M, Krarup-Hansen A, Hovgaard D, Petersen MM, Loya AC, Westergaard MCW, Svane IM, Junker N. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes. Cancer Immunol Immunother. 2020;69(11):2179–2191. doi:10.1007/s00262-020-02568-x.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, Angelo SD, Attia S, Riedel RF, Priebat DA, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone. Lancet Oncol. 2017;2045(17):1–9. doi:10.1016/S1470-2045(17)30624-1.
   Google Scholar
• Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, et al. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022;23(9):1156–1166. doi:10.1016/S1470-2045(22)00392-8.
   PubMed Web of Science ®Google Scholar
• Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991;51:3062–3066.
   PubMed Web of Science ®Google Scholar
• Gaspar D, Salomé Veiga A, Castanho MARB. From antimicrobial to anticancer peptides. A review. Front Microbiol. 2013;4(OCT):1–16. doi:10.3389/fmicb.2013.00294.
   PubMedGoogle Scholar
• Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF. Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 2012;119(24):5688–5696. doi:10.1182/blood-2011-10-386482.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233–5239. doi:10.1200/JCO.2008.16.5449.
   PubMed Web of Science ®Google Scholar
• Patterson S, Gross J, English N, Stackpoole A, Bedford P, Knight SC. CD4 expression on dendritic cells and their infection by human immunodeficiency virus. J Gen Virol. 1995;76(5):1155–1163. doi:10.1099/0022-1317-76-5-1155.
   PubMedGoogle Scholar
• Collin M, Herbein G, Montaner L, Gordon S. PCR analysis of HIV1 infection of macrophages: virus entry is CD4-dependent. Res Virol. 1993;144(C):13–19. doi:10.1016/S0923-2516(06)80006-3.
   PubMedGoogle Scholar